Endpoints News· Ayisha Sharma·· 3 天前AI 评分82
ESMO26：Amgen 的 Imdelltra 联合方案在 III 期肺癌试验中将死亡风险降低逾一半
#ESMO26: Amgen's Imdelltra regimen more than halves risk of death in Phase 3 lung cancer trial
正文 · 原文
MADRID — Amgen’s Imdelltra combined with AstraZeneca’s Imfinzi slashed the chances of dying by 58% versus Imfinzi alone in the first-line maintenance setting in certain small …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源：Endpoints News · endpoints.news